Appointment of Experienced Biotech Industry Veteran and Wall Street Executive to Spearhead Cytocom’s Future...
has been demonstrated in phase II clinical trials for Crohn’s Disease, HIV/AIDS, Fibromyalgia, MS, Autism and Cancer that in the presence of LDN, the numbers of T-cells, both CD4+ helper T cells and CD8+ cytotoxic T cells, may increase by more than 300%.
The OGF-OGFr peptide and receptor have been detected in a wide variety of cancers, including thyroid cancer (e.g. follicular-derived thyroid cancers), ovarian cancer, triple negative breast cancer, hepatocellular carcinoma, squamous cell carcinoma of the head and neck, pancreatic cancer, renal cancer, neuroblastoma, and colon cancer.
LATEST COMPANY EVENTS